Evidence map›Paper›PMID 37540248›Full record

ReviewWorld journal of urology2023

Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?

Filip Sydén, Joyce Baard, Matthew Bultitude, Francis Xavier Keeley, Morgan Rouprêt, Kay Thomas, Tómas Andri Axelsson, Georg Jaremko, Helene Jung, Camilla Malm and 3 more

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Filip SydénDepartment of Urology, Stockholm South General Hospital, Stockholm, Sweden.
Joyce BaardDepartment of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Matthew BultitudeGuy's and St. Thomas' NHS Foundation Trust, Urology Centre/Stone Unit, Guy's and St. Thomas' Hospital, London, UK.
Francis Xavier KeeleyBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Morgan RouprêtSorbonne University, Pitié Salpétrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
Kay ThomasGuy's and St. Thomas' NHS Foundation Trust, Urology Centre/Stone Unit, Guy's and St. Thomas' Hospital, London, UK.
Tómas Andri AxelssonDepartment of Surgery and Urology, Danderyd Hospital, Stockholm, Sweden.
Georg JaremkoDepartment of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
Helene JungDepartment of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Camilla MalmDepartment of Urology, Stockholm South General Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-1564-0011
Silvia ProiettiUrology Department, San Raffaele Hospital, Milan, Italy.
Palle Jørn Sloth OstherDepartment of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Marianne BrehmerDepartment of Urology, Stockholm South General Hospital, Stockholm, Sweden. marianne.brehmer@ki.se.ORCID http://orcid.org/0000-0001-9232-363X
Karolinska Institutet · SELillebaelt Hospital · DKStockholm South General Hospital · SESt Thomas' Hospital · GBAmsterdam University Medical Centers · NLDanderyds sjukhus · SENorth Bristol NHS Trust · GBSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo summarise the current knowledge regarding diagnostics, prognostication and follow-up in upper tract urothelial carcinoma (UTUC).

methodsA scoping review combined with expert opinion was applied to provide an overview of the current research field. Based on the published literature and the experts' own experience and opinions, consensus was reached through presentations and discussions at the meeting Consultation on UTUC II in Stockholm 2022.

resultsThe strongest prognostic factors in UTUC are tumour grade and stage. They are correlated, and grade is used for indirect staging. The diagnostic examinations should include multiphase computed tomography urography (CTU) with corticomedullary phase, and urethrocystoscopy with cytology. If there is no clear diagnosis for clinical decision-making, ureterorenoscopy (URS) with focal cytology and biopsies should be performed. Both WHO classification systems (1973/1999 and 2004/2016) should be used. Novel biomarker tests are not yet widespread nor recommended for the detection of UTUC. Long-term, regular follow-up, including URS in patients who have had organ-sparing treatment, is important to check for tumour recurrences, intravesical recurrences, metastases and progression of the tumour.

conclusionProper diagnostics with correct grading of UTUC are necessary for appropriate treatment decisions. The diagnostics should include CTU with corticomedullary phase, urine or bladder cytology, URS with focal barbotage cytology, and biopsies when needed for proper diagnosis and risk stratification. Regular, long-term follow-ups are fundamental, due to the high rate of recurrence and risk of progression.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsUreteral NeoplasmsUrinary Bladder NeoplasmsFollow-Up StudiesHumansNeoplasm Recurrence, LocalBiopsyComputed tomography urographyCytologyDiagnosticsFollow-upPrognosticationUpper tract urothelial carcinomaUreterorenoscopyUTUC

Identifiers

PMID37540248
PMCPMC10693525
OpenAlexW4385564846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.